NAVB
Navidea Biopharmaceuticals Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Market Cap: 8.04 Million
Primary Exchange: NYSE MKT LLC
Website: https://www.navidea.com/
Shares Outstanding: 100 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.0
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 1951 trading days
From: 2013-03-11 To: 2020-06-05
Lowest Point:
Navidea Biopharmaceuticals Announces Proposed Public Offering of Common Stock
via: Business Wire at 2019-06-13 13:31:00:000
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it intends to offer and sell shares of its common stock in a… read more...
Navidea Biopharmaceuticals Regains Direct Control of Intellectual Property
via: Business Wire at 2019-06-13 12:24:00:000
On June 12, 2019, Vice Chancellor Joseph Slights of the Court of Chancery of the State of Delaware issued an oral ruling granting the motion of Macrophage Therapeutics, Inc. (MT), a subsidiary of Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea … read more...
Microcaps dominate midday movers
via: SeekingAlpha at 2019-06-12 08:39:07:000
Gainers: Synlogic (NASDAQ: SYBX ) +28% . Immuron (NASDAQ: IMRN ) +26% . B Communications (NASDAQ: BCOM ) +23% . Arcadia Biosciences (NASDAQ: RKDA ) +17% . Vuzix Corporation (NASDAQ: VUZI ) +14% . MagnaChip Semiconductor Corporation (NYSE: MX ) +13% . Osmotica Pharmaceuticals (N… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|